Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — December 2023

Genmab — December 2023

Planlagt Fastgjort Låst Flyttet Genmab
860 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #96

    ESMO Immuno-Oncology 2023 Poster online- HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo https://cslide.ctimeetingtech.com/immuno23hybrid/attendee/confcal/presentation/list?q=148P+ "A first-in-human clinical trial is planned " I am assuming this is the #6 in the BioNTech cooperation.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #97

      ESMO Immuno-Oncology 2023 Poster - Safety and Antitumor Activity of GEN1042 in Combination with Pembrolizumab _ Chemotherapy in Solid Tumors: Phase 2b Dose-Expansion Trial in Progress https://cslide.ctimeetingtech.com/immuno23hybrid/attendee/confcal/presentation/list?q=160TiP+

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #98

        Genmab hæves til "køb" hos schweizisk storbank https://www.proinvestor.com/investornyt/1086822/genmab-haeves-til-kob-hos-schweizisk-storbank

        1 Reply Last reply
        0
        • K Offline
          K Offline
          Klarussen
          wrote on sidst redigeret af
          #99

          På tide

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #100

            Sounds promissing, “ encouraging early clinical activity, including complete responses”.

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #101

              Plural CRs in heavy treated pts. Very interesting !

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #102

                agree, very early ofcourse, but the news we are getting so far seems promising !

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  lahn1
                  wrote on sidst redigeret af
                  #103

                  Doesn't this support our thinking yesterday, that the expansion of trial pts. is a possitiv sign ?

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #104

                    I would think so, yes. Let's hope we'll get some comments on it next week.

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #105

                      "OX40 has been implicated in the pathologic cytokine storm associated with certain viral infections, including the H5N1 bird flu" If it doesn't work in solid tumors ; Biontech knows how to create vaccins 😉 https://en.wikipedia.org/wiki/CD134

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #106

                        I find it comforting that BioNTech is willing to try the second Hexabody. After all, the technology has not yet been proven. But it would not surprise me if they have also seen the data on Hexabody-DR5/DR5 . Doubt they are allowed to see Hexabody-CD38 data early though.

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #107

                          Genmab har ændret gen1046 til acasunlimab på deres hjemmeside, men har (endnu) ikke ændret gen1042. Så vi mangler den endelige beslutning.

                          1 Reply Last reply
                          0
                          • T Offline
                            T Offline
                            Teller
                            wrote on sidst redigeret af
                            #108

                            Det ser da lovende ud, mon KYSO moment er i sigte? 🙂

                            1 Reply Last reply
                            0
                            • K Offline
                              K Offline
                              Klarussen
                              wrote on sidst redigeret af
                              #109

                              Hvor er det smukt (Genmab IR): "We have committed to a new vision for our future that by 2030, our knock-your-socks-off KYSO antibody medicinesTM are fundamentally transforming the lives of people with cancer and other serious diseases."

                              1 Reply Last reply
                              0
                              • FrittenF Offline
                                FrittenF Offline
                                Fritten
                                wrote on sidst redigeret af
                                #110

                                Spændende artikel om 5 store ting på ASH, hvor de nævner Genmab som 1 af dem:

                                1 Reply Last reply
                                0
                                • FrittenF Offline
                                  FrittenF Offline
                                  Fritten
                                  wrote on sidst redigeret af
                                  #111

                                  https://firstwordpharma.com/story/5807409?from=article

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    ProinvestorNEWS
                                    wrote on sidst redigeret af
                                    #112

                                    Johnson & Johnson’s prescription for growthhttps://www.proinvestor.com/investornyt/1087102/johnson-amp-johnsonrsquos-prescription-for-growth

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      ProinvestorNEWS
                                      wrote on sidst redigeret af
                                      #113

                                      "Key pharmaceuticals like Darzalex, Carvykti, and Stelara are pivotal revenue drivers, illustrating J&J's steadfast commitment to developing and delivering life-altering treatments. These flagship drugs continue to showcase robust market demand, underpinning the company's revenue expectations"
                                      .

                                      1 Reply Last reply
                                      0
                                      • T Offline
                                        T Offline
                                        Teller
                                        wrote on sidst redigeret af
                                        #114

                                        God formiddag 🙂

                                        1 Reply Last reply
                                        0
                                        • H Offline
                                          H Offline
                                          Hen
                                          wrote on sidst redigeret af
                                          #115

                                          😉

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper